Spread | 0.07 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 7.57 |
Open | 7.74 |
1-Year Change | 71.24% |
Day's Range | 7.41 - 7.84 |
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.
BRIEF: For the nine months ended 30 September 2021, Larimar Therapeutics Inc revenues was not reported. Net loss increased 47% to $41.5M. Higher net loss reflects Research and Development increase of 50% to $30.6M (expense), Stock-based Compensation in SGA increase from $709K to $2.5M (expense), Stock-based Compensation in R&D increase from $442K to $1.5M (expense).
Common Stock, $0.001 Par, 06/14, auth. 115M shares,. 20,807,012 issd,. Insiders owns approx. 28.83%.